Clinical trial NCT05844605: Prehabilitation, Rehabilitation and Comprehensive Approach to the Sequelae of Brain Tumors
Official title: Joan Ribas Araquistain Program for Research and Therapeutic Innovation in Prehabilitation, Rehabilitation and Comprehensive Approach to the Sequelae of Brain Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Brain Tumor
Keywords: brain tumour
prehabilitation
neuromodulation
motor training
cognitive training
Lead sponsor: Institut Guttmann
Sponsor class: OTHER
First posted: 2023-05-06
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Pilot single-cohort feasibility open-label trial
Primary purpose: TREATMENT

Brief summary: The goal of the present pilot single-cohort feasibility trial is to investigate the feasibility and understand potential mechanisms of efficacy for Neuromodulation-Induced Cortical Prehabilitation (NICP) in adults with brain tumours and eligible for neurosurgery.

The main questions it aims to answer are:

* is the intervention feasible, in terms of adherence, retention, safety and patient's satisfaction;
* what are the mechanisms of neuroplasticity primed by NICP

Participants will undergo a prehabilitation protocol, consisting of daily sessions (total: 10-20 sessions) structured as follows:

* Intervention 1: non-invasive neuromodulation (TMS/tDCS).
* Intervention 2: motor and/or cognitive training, during or immediately after non-invasive neuromodulation, for about 60 minutes.

The timeline is structured as follows:

T1: baseline (before NICP) T2-T3: NICP period T4: after NICP T5: surgery T6: after surgery

Clinical, neuroimaging and neurophysiology assessments will be performed before NICP (T1), after NICP (T4), and after neurosurgery (T6). Feasibility outcomes will be determined during NICP protocol (T2-T3).

The objective of the proposed intervention is to progressively reduce the functional relevance of eloquent areas, which are healthy brain areas close with the tumour and thus exposed to the risk of being lesioned during surgery. In fact, previous studies have shown that temporary inhibition of eloquent areas (by neuromodulation) coupled with intensive motor/cognitive training promoted the activation of alternative brain resources, with a shift of functional activity from eloquent areas to areas functionally related, but anatomically distant from the tumour.

By moving the activation of key motor/cognitive functions away from the tumour, the risk of postoperative functional sequelae will be reduced; which in turn will falicitate a more radical tumour excision by the neurosurgeon.

Detailed description: Neuromodulation-Induced Cortical Prehabilitation (NICP) is a relatively new approach in the neurosurgical field. It consists of priming neuroplastic changes before neurosurgery for brain tumours, in order to improve surgical outcomes and, hopefully, long-term survival and quality of life. The intervention comprises two elements:

1. Neuromodulation (like transcranial magnetic stimulation, TMS, and transcranial direct current stimulation, tDCS). The goal of neuromodulation is to inhibit the eloquent areas, defined as brain areas functionally active and close to the tumour.
2. Behavioural training (like motor training, cognitive training, or a combination). The function trained corresponds with the function of the eloquent area targeted by neuromodulation.

The two interventions are provided on a daily basis, and repeated over 10-20 consecutive weekdays. Notably, after the inhibition of the eloquent area there is a temporal window of about one hour, where intensive training of the same function requires the activation of alternative areas/pathways. By consolidating this alternative activation over multiple sessions, the outcome is a reduction in the functional relevance of eloquent areas, in favour of alternative resources anatomically distant from the tumour.

Only few case reports have been published so far, with very positive results obtained by means of invasive neuromodulation; the term 'invasive' means that a first neurosurgery was required to implant electrodes over eloquent areas for intracranial electrical stimulation, followed after few days/weeks by a second surgery for tumour removal. Despite relevant neuroplastic changes, the problem with this approach has been the high rate of adverse events occurred (infections, edema, pain, seizure) due to the invasiveness of the procedures. Therefore, by using a non-invasive neuromodulation approach, the goal of the present trial is to promote neuroplastic changes beneficial for neurosurgery, while at the same time ensuring no serious adverse events.

Further details on neuromodulation. Investigators will apply the most appropriate neuromodulation protocol, personalized based on whether to perform TMS and/or tDCS, individual resting motor threshold (for TMS), and target determination (related to eloquent areas).

Protocol for low frequency rTMS:

* intensity: 90% RMT;
* frequency: 1 Hertz;
* total number of pulses: 1600.

Protocol for tDCS:

* cathode: over eloquent areas
* anode: typically over areas that should be activated, as opposed to eloquent areas

Further details on upper limb prehabilitation training.

Within the 60 minutes immediately after neuromodulation, patients will perform an intensive training of the same function of the eloquent area, which is now temporarily inhibited. Intensity of the training will be continuously adjusted in terms of type, difficulty and variability:

* Type: exercises specific for finger individuation (play the piano, typewriting), finger coordination (dexterity, manipulation), arm reaching. In order to integrate upper limb function with other motor-cognitive functions, dual task training will be performed, both motor-cognitive (decision making, stroop task, motor sequence learning etc.) and motor-motor (bimanual activites, arm and balance tasks, etc.);
* Difficulty: the intensity of the exercise will be set as to result 'difficult, yet achievable' by the patient. This way it is ensured that the brain is under a stress condition which, together with concurrent eloquent area inhibition, will promote and consolidate the activation of alternative resources.
* Variability: varying systematically the type and difficulty of the training is useful to keep the patient engaged and ensure that the end result will be a global motor-cognitive training, instead of a monotonic improvement in a specific performance.

Further details on Prehabilitation for language and cognitive training. Language-cognitive training will follow the same rationale illustrated for motor training. Soon after neuromodulation the patient will perform a computerized cognitive training on a dedicated platform ("Guttmann NeuroPersonalTrainer"® (GNPT). Exercises will be customized based on specific patient's deficits, and/or functions at risk of being compromised after surgery. For instance, the neuropsychologist may vary settings such as presentation speed, latency time or number of images, thus finely tuning several difficulty levels. Regarding language, tasks will be planned and supervised in a personalized way by a neuropsychologist, readjusting their planning if necessary.

Discontinuation, adherence, and permission for concomitant care.

The intervention will be discontinued in the following cases:

* participant's request;
* serious adverse events attributable to the intervention. Patients will be allowed to continue any ongoing treatment. Formal training of motor-cognitive functions outside the protocol will be discourage, as it may affect neuroplastic changes in an unpredictable way.

Eligibility criteria: Inclusion Criteria:

* diagnosis of brain tumour requiring neurosurgery
* ability to undertake at least 10 sessions of prehabilitation protocol
* tumour location posing the patient at risk of developing post-operative neurological deficits, for instance at the level of upper limb motor function and speech production
* ability to understand the general purpose of the prehabilitation program and understand simple instructions
* being willing to participate and sign the informed consent
* being able to sit unassisted for one hour.

Exclusion Criteria:

* any contraindication for magnetic resonance imaging or transcranial magnetic stimulation
* unstable medical conditions
* musculoskeletal disorders that may significantly affect functional training
* pain, depression, fatigue that may significantly affect functional training
* history of alcohol/drug abuse

Primary outcomes:
measure: Feasibility_adherence
timeFrame: Throughout the intervention, which will last approximately 10 to 20 sessions (two to four weeks)
measure: Feasibility_retention
timeFrame: Throughout the intervention, which will last approximately 10 to 20 sessions (two to four weeks)
measure: Feasibility_safety
timeFrame: Throughout the intervention, which will last approximately 10 to 20 sessions (two to four weeks)
measure: Feasibility_patient's satisfaction
timeFrame: Throughout the intervention, which will last approximately 10 to 20 sessions (two to four weeks)
Secondary outcomes:
measure: Clinical_Neurological Assessment in Neuro-Oncology (NANO) scale
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_Karnofsky Performance Status
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_upper limb_9 Hole Peg Test
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_upperl limb_Fugl-Meyer Upper Extremity
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_upper limb_Hand dynamometer
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_upper limb_Deary-Liewald reaction time task
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_lower limb and balance_Fugl Meyer Lower Extremity
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_lower limb and balance_Brunel Balance Assessment
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_lower limb and balance_Six minute walking test
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_EORTC-QLQ-C30*
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_EORTC-BN20
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_EORTC-FA12
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_Revised Barcelona Test
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_WAIS-III Wechsler Adult Intelligence Scale
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_Trail Making Test
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_Continuous Performance Test-III
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_Rey Auditory Verbal Learning Test
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_WMS-IV Wechsler Memory Scale
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_Symbol Digit Modalities Test
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_PMR Verbal fluency by letters.
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_Hayling Test
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_Wisconsin Card Sorting Test
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Clinical_Hospital Anxiety and Depression Scale
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Neuroimaging_structural MRI
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Neuroimaging_resting state fMRI
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Neuroimaging_fMRI_Word generation task
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Neuroimaging_fMRI_Semantic decision task
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Neuroimaging_fMRI_Comprehensive auditive task
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Neuroimaging_fMRI_Finger tapping task
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Neuroimaging_fMRI_Ankle flexion task
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Neuroimaging_fMRI_Tongue movement task
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Neurophysiology_TMS mapping_hotspot
timeFrame: Baseline (before the intervention protocol)
measure: Neurophysiology_TMS mapping_resting motor threshold
timeFrame: Baseline (before the intervention protocol)
measure: Neurophysiology_TMS mapping_motor function
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Neurophysiology_TMS mapping_language function
timeFrame: At baseline (before the intervention), at the end of the intervention (but before neurosurgery), and at the first available follow up (from one month up to one year after surgery)
measure: Surgical outcomes
timeFrame: Within the first week after surgery
Other outcomes:
Locations:
city: Badalona
country: Spain
facility: Institut Guttmann
state: Cataluña
Study officials:
References:
citation: Duffau H. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. Lancet Neurol. 2005 Aug;4(8):476-86. doi: 10.1016/S1474-4422(05)70140-X.
citation: Rivera-Rivera PA, Rios-Lago M, Sanchez-Casarrubios S, Salazar O, Yus M, Gonzalez-Hidalgo M, Sanz A, Avecillas-Chasin J, Alvarez-Linera J, Pascual-Leone A, Oliviero A, Barcia JA. Cortical plasticity catalyzed by prehabilitation enables extensive resection of brain tumors in eloquent areas. J Neurosurg. 2017 Apr;126(4):1323-1333. doi: 10.3171/2016.2.JNS152485. Epub 2016 May 20.
citation: Duffau H. Can Non-invasive Brain Stimulation Be Considered to Facilitate Reoperation for Low-Grade Glioma Relapse by Eliciting Neuroplasticity? Front Neurol. 2020 Nov 12;11:582489. doi: 10.3389/fneur.2020.582489. eCollection 2020. No abstract available.
citation: Hamer RP, Yeo TT. Current Status of Neuromodulation-Induced Cortical Prehabilitation and Considerations for Treatment Pathways in Lower-Grade Glioma Surgery. Life (Basel). 2022 Mar 22;12(4):466. doi: 10.3390/life12040466.
citation: Barcia JA, Sanz A, Gonzalez-Hidalgo M, de Las Heras C, Alonso-Lera P, Diaz P, Pascual-Leone A, Oliviero A, Ortiz T. rTMS stimulation to induce plastic changes at the language motor area in a patient with a left recidivant brain tumor affecting Broca's area. Neurocase. 2012;18(2):132-8. doi: 10.1080/13554794.2011.568500. Epub 2011 Jul 25.
citation: Barcia JA, Sanz A, Balugo P, Alonso-Lera P, Brin JR, Yus M, Gonzalez-Hidalgo M, Acedo VM, Oliviero A. High-frequency cortical subdural stimulation enhanced plasticity in surgery of a tumor in Broca's area. Neuroreport. 2012 Mar 28;23(5):304-9. doi: 10.1097/WNR.0b013e3283513307.
citation: Serrano-Castro PJ, Ros-Lopez B, Fernandez-Sanchez VE, Garcia-Casares N, Munoz-Becerra L, Cabezudo-Garcia P, Aguilar-Castillo MJ, Vidal-Denis M, Cruz-Andreotti E, Postigo-Pozo MJ, Estivill-Torrus G, Ibanez-Botella G. Neuroplasticity and Epilepsy Surgery in Brain Eloquent Areas: Case Report. Front Neurol. 2020 Jul 29;11:698. doi: 10.3389/fneur.2020.00698. eCollection 2020.
citation: Hoogendam JM, Ramakers GM, Di Lazzaro V. Physiology of repetitive transcranial magnetic stimulation of the human brain. Brain Stimul. 2010 Apr;3(2):95-118. doi: 10.1016/j.brs.2009.10.005. Epub 2009 Nov 24.
citation: Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmoller J, Carpenter LL, Cincotta M, Chen R, Daskalakis JD, Di Lazzaro V, Fox MD, George MS, Gilbert D, Kimiskidis VK, Koch G, Ilmoniemi RJ, Lefaucheur JP, Leocani L, Lisanby SH, Miniussi C, Padberg F, Pascual-Leone A, Paulus W, Peterchev AV, Quartarone A, Rotenberg A, Rothwell J, Rossini PM, Santarnecchi E, Shafi MM, Siebner HR, Ugawa Y, Wassermann EM, Zangen A, Ziemann U, Hallett M; basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines", Siena, October 17-20, 2018, updating through April 2020. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 Jan;132(1):269-306. doi: 10.1016/j.clinph.2020.10.003. Epub 2020 Oct 24.
citation: Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipovic SR, Grefkes C, Hasan A, Hummel FC, Jaaskelainen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen JP, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorova I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol. 2020 Feb;131(2):474-528. doi: 10.1016/j.clinph.2019.11.002. Epub 2020 Jan 1.